Canada
· Delayed Price · Currency is CAD Defence Therapeutics Company Description
Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases.
The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; anti-cancer AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma; ARM-X vaccine program, a mesenchymal stem cell-based vaccine targeting cancer; and mRNA vaccination program.
It also offers Accuvac for dendritic cell cancer vaccines; a protein‐based vaccine formulation against COVID and infectious diseases; and cervical cancer vaccine.
The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020.
The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
| Country | Canada |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Sebastien Plouffe |
Contact Details
Address: 1680 – 200 Burrard Street Vancouver, British Columbia V6C 3L6 Canada | |
| Phone | 514 947 2272 |
| Website | defencetherapeutics.com |
Stock Details
| Ticker Symbol | DTC |
| Exchange | Canadian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | CAD |
| ISIN Number | CA24463V1013 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Sebastien Plouffe | Chief Executive Officer, President and Director |
| Patrick Joseph Meagher C.A., CPA, CA, CPA | Chief Financial Officer and Director |
| Dr. Moutih Rafei Ph.D. | Chief Scientific Officer and Director |
| Dr. Simon Beaudoin | Chief Technical Science Officer |
| Carrie Cesarone | Corporate Secretary |